Tackling fibrosis, increasing healthspan

GAT Therapeutics is an early stage biopharma targeting fibrosis and age-related diseases.

Tackling fibrosis, increasing healthspan

GAT Therapeutics is an early stage biopharma targeting fibrosis and age-related diseases.

Pipeline

.

GTX-011 is a first-in-class, nonsteroidal, selective 3-ketosteroid nuclear receptor modulator (NR3C family). We believe it has the potential to become mainstay therapy in liver fibrosis and myelofibrosis, a devastating rare disease with no cure today.

Team

Our scientists partner with academia and leading clinical

research organizations (CROs) to translate our discoveries to patient outcomes

Jaume

CEO, CTO

Noe

MedChem Manager

Eugenia

R&D Manager

Joan

CBO

News

12/2019 I PRESS RELEASE

GAT Therapeutics secures 1 Million EUR from CDTI

GAT Therapeutics, a fully owned subsidiary of Greenaltech, has secured 1 Million EUR in non-dilutive financing from CDTI to help the company accelerate the preclinical development of its leading drug candidate GTX-011 targeting liver fibrosis and myelofibrosis.

03/2020 I PRESS RELEASE

GAT Therapeutics partners with Barcelona Liver Bioservices

GAT Therapeutics announced today a non-exclusive partnership with Barcelona Liver Bioservices (BLB) to characterize the effects of its leading drug candidate GTX-011 for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).

Contact us

Nuevo campo

3 + 4 =

Parc Científic de Barcelona
C/Baldiri Reixac 4
08028 Barcelona (Spain)

+34 93 447 27 34

info@gattx.com

Terms of use |
Privacy statement

2020 I GAT Therapeutics. All rights reserved